Trial Information
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of orBec® (Oral Beclomethasone 17,21-Dipropionate)in Conjunction With Ten Days of High-Dose Prednisone Therapy in the Treatment of Patients With Gastrointestinal GVHD
Inclusion Criteria:
- Receipt of allogeneic hematopoietic cell transplant
- Diagnosis of GI graft vs. host disease (GVHD)
- No GI infection
- Must be able to swallow tablets
- Must be able to read and understand informed consent
- Adequate birth control methods for the duration of the study
Exclusion Criteria:
- Significant Skin GVHD
- Liver GVHD
- Persistent vomiting
- HIV positive
- Pregnancy/lactation
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Outcome Measure:
The proportion of subjects with GVHD treatment failure
Outcome Time Frame:
Day 80
Safety Issue:
No
Principal Investigator
Keith Sullivan, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Duke University
Authority:
United States: Food and Drug Administration
Study ID:
BDP-GVHD-03
NCT ID:
NCT00926575
Start Date:
October 2009
Completion Date:
May 2012
Related Keywords:
- Acute Gastrointestinal Graft vs Host Disease
- BDP
- orBec
- GVHD
- beclomethasone dipropionate
- bone marrow transplant
- hematopoietic cell transplant
- HCT
- stem cell transplant
- marrow transplant
- SCT
- beclomethasone 17,21-dipropionate
- Graft vs Host Disease
Name | Location |
|
Albany, New York 12208 |
|
Seattle, Washington 98195 |
|
Charlotte, North Carolina |